People · Operator
Named in public records as an officer, director or promoter · active 2010–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cardiodx Inc | — | Biotechnology | Series C | $174.0M | $742.4M | 2010 |
| Roka BioScience, Inc. | — | Biotechnology | Series B | $141.4M | $893.0M | 2016 |
| Proteogenix Inc | — | Biotechnology | Series A | $8.0M | $144.6M | 2010 |
Fred G. Cohen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Fred G. Cohen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Fred Cohen | 2 | 12 |
| David Levison | 2 | 3 |
| Brook Byers | 1 | 13 |
| Michael Goldberg | 1 | 11 |
| Jonathan Silverstein | 1 | 10 |
| Patrick Enright | 1 | 10 |
| Risa Stack | 1 | 9 |
| Vijay Lathi | 1 | 8 |
| G. Steven Burrill | 1 | 7 |
| Patrick G. Enright | 1 | 7 |
| James R. Tobin | 1 | 6 |
| William Ericson | 1 | 6 |
| Ajit Singh | 1 | 5 |
| Louis G. Lange | 1 | 4 |
| Arthur M. Pappas | 1 | 3 |
| Brook H Byers | 1 | 3 |
| Mike Allen | 1 | 3 |
| Fred J Cohen | 1 | 2 |
| Andrew L. Guggenhime | 1 | 2 |
| Douglas T. Ross | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.